Lipid Sciences, Inc. Granted Second HDL Selective Delipidation Patent
Published: May 27, 2008
PLEASANTON, CA--(Marketwire - May 27, 2008) - Lipid Sciences, Inc. (NASDAQ: LIPD) announced the issuance of a second patent covering the Company's HDL Selective Delipidation technology. U.S. Patent No. 7,375,191 further extends Lipid Sciences' ownership over therapeutic HDL compositions provided by the Company's proprietary extracorporeal delipidation process. This new patent, together with Patent No. 7,361,739 issued on April 22, 2008, creates a broad ownership position in this important therapeutic space. The Company plans to capitalize on this strong IP position and recent encouraging clinical trial data by aggressively pursuing ongoing partnership discussions supporting commercialization of this promising medical technology.